BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients ……
The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.
Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.
Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.
by Christine Clark ISHL 2016 Professor Joseph Connors (Vancouver) speaks about the session at ISHL10 where a world view of the management of Hodgkin lymphoma was discussed. There… read more.
Dr Sridhar Chaganti, University Hospital, Birmingham NHS Foundation Trust, UK. by Christine Clark: In general the outcomes of treatment for diffuse large B-cell lymphoma (DLBCL) are good –… read more.
Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.
Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.
Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.
Firmagon (Degarelix) is a competitive, reversible GnRH receptor blocker, for patients with advanced hormone-dependent prostate cancer. Where Injection technique is critical; Nora Sullivan, a specialist nurse at Hibernian… read more.
by Christine Clark: The National Cancer Information Network (NCIN) was established to drive change and improve cancer outcomes. Analyses show large variations in practices and outcomes some of… read more.
Graham Jackson, Professor of Clinical haematology, Newcastle upon Tyne and former president of the British Society for Haematology (BSH). Article by Christine Clark: In the 1970s the prospect… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
